Synergy IMT creates antibody and recombinant protein-based therapeutics targeting promising novel tumor antigens.

Synergy IMT has identified multiple novel tumor antigens, some of which possess tumor growth regulating activity.  These antigens are differentially expressed on a broad range of tumor types including but not limited to, colon, pancreatic, gastric, and  breast. These antigens have not been detected on normal cells.  

Antibodies, antibody drug conjugates (ADCs) and recombinant proteins, that target these antigens and/or their activity, demonstrate very significant tumor growth inhibition.  These drug candidates are well tolerated in a multidose toxicity study. Multiple patents have been filed that cover these novel targets.

Bi- and tri-specific antibodies, including T cell engagers (TCEs), have also been created that potently kill a broad range of tumor cell types. Certain candidates are designed to both eliminate tumor cells and to modify the composition of the tumor microenvironment to stimulate a synergistic and durable anti-tumor response.

Synergy IMT is focused on progressing an initial candidate into clinical studies and forming collaborations around other candidates.

Synergy IMT integrates AI driven software throughout development, from discovery to IND.